Bvf Inc Aclaris Therapeutics, Inc. Transaction History

Bvf Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $24.3 Million - $40.6 Million	3,703,795 Added 110.2%	7,064,736 $48.4 Million
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $596,693 - $1.51 Million	84,398 Added 2.58%	3,360,941 $27.2 Million
Q4 2022 Feb 14, 2023	SELL	$14.33 - $18.37 $10 Million - $12.9 Million	-700,000 Reduced 17.6%	3,276,543 $51.6 Million
Q1 2022 May 16, 2022	BUY	$9.74 - $17.92 $22.2 Million - $40.9 Million	2,280,639 Added 134.48%	3,976,543 $68.6 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $3.96 Million - $5.97 Million	322,860 Added 23.51%	1,695,904 $24.7 Million
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $4.99 Million - $7.01 Million	373,044 Added 37.3%	1,373,044 $24.7 Million
Q2 2021 Aug 16, 2021	BUY	$17.08 - $29.6 $17.1 Million - $29.6 Million	1,000,000 New	1,000,000 $17.6 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $271M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.